Abstract
Psoriatic disease (PsD) is associated with metabolic dysfunction-associated steatotic liver disease (MASLD), but the hepatic effects of biologic therapies are unclear. We evaluated paired liver MRI and multi-modal immunoprofiling in PsD patients initiating new systemic therapy.
COLIPSO is a prospective cohort of adults with moderate-to-severe psoriasis or psoriatic arthritis (PsA) starting a new conventional synthetic or biologic disease-modifying antirheumatic drug (DMARD). Liver MRI was performed at baseline and ∼6 months. A subset of participants with PsA underwent peripheral blood flow cytometry and single-cell RNA sequencing (scRNAseq). Primary outcomes were within-subject change in quantitative MRI measures of liver disease activity and fat content (iron-corrected T1 [cT1] and proton density fat fraction [PDFF]). Bayesian models were used.
Thirty-five participants (mean age 50±13 years; 61% male) were followed for ∼29 weeks. Baseline disease activity was moderate (mean DAPSA 29) and 40% had MASLD. IL-17 inhibitors (IL-17i) improved PDFF (−1.58 ± 1.61%) and cT1(−43.6 ± 52.7ms), whereas TNFi showed little change. Compared with csDMARD, IL-17i improved PDFF (probability of direction [pd] 89%) and cT1 (pd 93%), which was not seen with TNFi. Flow cytometry (n=17) linked baseline γδ and ThGM-CSF T-cell abundance with cT1 and PDFF. scRNAseq highlighted baseline transcriptomic signatures in MAIT cells associated with cT1 and PDFF. Naïve T-cell RNA signatures at baseline were associated with MRI improvements.
In PsD, only IL-17i were associated with improved liver disease in addition to improving clinical PsD outcomes. T-cell subtypes bridging innate and adaptive immunity were associated with liver disease features.
Key messages
IL-17 inhibition was associated with a significant reduction in hepatic steatosis (PDFF) and liver inflammatory disease activity (cT1).
Baseline γδ and ThGM-CSF T cell abundance was associated with cT1 and PDFF, and γδ T cells and cT1 and PDFF co-varied over follow up. Distinct gene expression signatures in MAIT and naïve CD4 T cells at baseline were associated with liver MRI parameters.
Our results support larger mechanistic and clinical studies to test if IL-17 pathway inhibition improves liver disease in PsD, and whether treatment decision algorithms should account for metabolic liver disease.
Competing Interest Statement
S.G., L.J., A.J.C.: none declared. C.D., A.A., and H.T.B. are employees at Perspectum, Ltd., the company that developed LiverMultiScan, the multiparametric MRI method used in this study. H.T.B. is a shareholder at Perspectum, Ltd. H.A.M has worked as a paid consultant and paid speaker for Novartis, Pfizer, UCB; has been on the advisory boards for Abbvie, Roche, Novartis; has share holdings in UCB, GSK, BMS; and has received grants (Personal fellowship) from UCB. H.M was previous employee at UCB, AstraZeneca and current employee of Immunocore. L.C.C has received grants/research support from Abbvie, Amgen, Janssen and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Enlivex, Janssen, Moonlake, Novartis, Oruka, Pfizer, Proximi-T, Sitryx, Takeda and UCB; and has been paid as a speaker for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee approval was granted by London - Bromley Research Ethics Committee (REF: 20/LO/0616). All patients provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data availability statement: Summary data is included in the manuscript or uploaded as online supplemental information. Anonymised individual patient data can be shared upon request or as required by law and/or regulation and/or governance by and within the rules of UK Biobank access with qualified external researchers. Approval of such requests is at the discretion of the study sponsors and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data.
Funder Information Declared
